Most Promising New Treatments for Multiple Myeloma — Bispecific Antibodies, Next-Generation CAR-T Cell Therapy, CELMoDs, Antibody-Drug Conjugates, MRD Negativity, and the Question of a Functional Cure: A Structured Guide for International Patients, Families, and Physicians Considering Treatment Options or a Second Opinion in China

Multiple myeloma is a cancer of plasma cells — a type of white blood cell found in the bone marrow. For many years, the mainstay of treatment was built around proteasome inhibitors (such as bortezomib and carfilzomib), immunomodulatory drugs (such as lenalidomide and pomalidomide), and autologous stem cell transplant. Daratumumab, a CD38-targeted monoclonal antibody, transformed frontline treatment when it was added to these combinations.

The challenge with myeloma is that most patients eventually relapse. Even after responding well to initial treatment, the disease often returns — sometimes resistant to drugs that worked previously. This pattern of relapse and re-treatment has driven the search for therapies that can reach myeloma cells through entirely different mechanisms.

The newest generation of treatments approaches myeloma in fundamentally different ways: by redirecting the immune system directly against myeloma-specific surface proteins, by engineering more potent immunomodulatory compounds, and by delivering cytotoxic payloads directly to myeloma cells. The cumulative effect has been an expanding toolkit — and a growing conversation about whether some patients might achieve long-term disease control that approaches what could, informally, be described as a cure.

For international patients and families navigating these decisions, a structured online MDT consultation can help clarify which of these newer options may be relevant to a specific disease situation — and what evaluation would be required before any treatment decisions are made.

Bispecific T-cell engaging antibodies are one of the most discussed new additions to myeloma treatment. Unlike CAR-T therapy, which requires a patient's own T cells to be collected, engineered, and expanded in a manufacturing facility, bispecific antibodies are produced in advance and administered directly. This makes them more immediately accessible — no waiting for cell manufacturing, no complex collection logistics.

These drugs are engineered to bind simultaneously to two targets: a protein on the surface of myeloma cells, and CD3 — a protein on T cells. By forming this bridge, bispecific antibodies recruit the patient's own immune cells into proximity with myeloma cells, triggering an immune attack. Three bispecific antibodies for myeloma have received regulatory approvals in some countries:

A common side effect with bispecific antibodies is cytokine release syndrome (CRS) — a systemic inflammatory response that occurs when large numbers of immune cells are activated. CRS can range from mild (fever, fatigue) to severe, and is managed with supportive care and corticosteroids in experienced oncology centres. Neurotoxicity (ICANS) is less common than with CAR-T but remains a monitored risk. Taste changes and nail changes are specific to talquetamab, related to GPRC5D expression in non-myeloma tissues.

BCMA-targeted CAR-T therapies — including ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) — have been approved in several countries for relapsed or refractory myeloma. What makes the newer data particularly noteworthy is not just the response rates in heavily pre-treated patients, but the durability of those responses in certain individuals.

Extended follow-up data from the CARTITUDE-1 trial with cilta-cel showed that a proportion of patients who achieved deep responses remained in remission at four years — a timeframe that would have been unusual in triple-class refractory myeloma with previous therapies. The CARTITUDE-4 trial investigated cilta-cel in patients with earlier relapse (one to three prior lines), and showed statistically significant improvement in progression-free survival compared with standard therapy — raising the question of whether earlier use of CAR-T might lead to even more durable outcomes.

China has active CAR-T programs for multiple myeloma, and international patients may access structured evaluation through CAR-T coordination in China. Chinese oncology centres have developed BCMA-targeted CAR-T constructs that are being studied in clinical trials, and the infrastructure for leukapheresis, manufacturing, and post-infusion monitoring is established at major haematology centres. For patients considering this pathway, understanding the eligibility evaluation process is an important first step — which our related guide on CAR-T eligibility for myeloma covers in more detail.

Immunomodulatory drugs (IMiDs) — including thalidomide, lenalidomide, and pomalidomide — have been backbone agents in myeloma treatment for many years. CELMoDs (cereblon E3 ligase modulators) are a newer class that works through a related but distinct mechanism: they bind to the same molecular target (the CRL4-CRBN E3 ubiquitin ligase complex) but with greater potency and a different binding profile, meaning they may remain active even when the standard IMiDs have stopped working.

CELMoDs are primarily in clinical trial settings at present and not yet widely approved as standard-of-care agents. Patients who may be eligible should discuss clinical trial access with their treating team or through a structured specialist review.

Antibody-drug conjugates (ADCs) are molecules that combine a targeting antibody with a cytotoxic (cell-killing) payload. The antibody directs the conjugate to myeloma cells, where the payload is released. This approach attempts to deliver chemotherapy-like activity precisely to cancer cells, potentially reducing systemic toxicity.

Belantamab mafodotin (Blenrep) targets BCMA and delivers a cytotoxic agent (monomethyl auristatin F) directly to myeloma cells. It has shown activity in relapsed/refractory myeloma, though its use requires careful monitoring for corneal changes (keratopathy), which is a class-specific side effect. Belantamab mafodotin is being studied in combination with other agents, and clinical trial results from combination approaches have shown improved response rates compared with single-agent use.

ADC development in myeloma extends beyond belantamab — newer BCMA-targeting and GPRC5D-targeting ADC constructs are in early-phase trials. The field is evolving, and the optimal role of ADCs relative to bispecific antibodies and CAR-T in the myeloma treatment sequence remains an area of ongoing clinical research.

One of the most significant shifts in frontline myeloma treatment has been the move toward quadruplet therapy — combining four agents rather than three. The addition of daratumumab to the standard triplet of bortezomib, lenalidomide, and dexamethasone (Dara-VRd) in newly diagnosed transplant-eligible patients has been shown to achieve MRD negativity in more than 60% of patients in some trials — a dramatically deeper response than was typical a decade ago.

MRD — measurable residual disease — refers to the small number of myeloma cells that may remain even after a patient achieves clinical remission on standard assessments. MRD testing uses highly sensitive methods (such as next-generation sequencing or multiparameter flow cytometry) to detect myeloma cells at levels as low as one in a million cells. Sustained MRD negativity — particularly when maintained over two or more years — has been associated with longer progression-free survival in multiple large trials.

The direction of the field — toward achieving the deepest possible early responses through combination therapy, followed by MRD-guided decisions — represents a meaningful shift in how specialists now think about long-term myeloma management. What this means for any given patient requires individual evaluation.

China has made significant investments in haematology and oncology infrastructure, including myeloma-specific treatment programs. Several aspects are relevant for international patients considering evaluation or treatment:

For families who want to understand what options may be available in China — and how to approach that evaluation — our broader guide on multiple myeloma treatment options provides a fuller overview of the standard treatment landscape as a starting context.

Newer myeloma treatments — including bispecific antibodies, CAR-T cell therapy, and intensified combination regimens — can be physically demanding. Managing side effects, maintaining nutritional status, supporting sleep and fatigue, and preserving quality of life during and after treatment are important parts of the overall care plan.

In China, oncology care at leading centres may include integrative supportive approaches alongside standard myeloma treatment — including Traditional Chinese Medicine (TCM), acupuncture, therapeutic nutrition, and fatigue and appetite management. These approaches are used as complementary care, not as replacements for chemotherapy, CAR-T therapy, bispecific antibody infusions, or other systemic treatments.

Supportive care is always used alongside, not instead of, prescribed oncology treatment. Patients and families interested in how integrative supportive care works alongside standard oncology treatment in China may find our resources on Traditional Chinese Medicine and supportive care useful as background context.

When speaking with a specialist about newer myeloma treatments, the following questions may help clarify whether a specific approach could be relevant to a particular situation:

Families facing relapsed or refractory myeloma — or those uncertain whether they have accessed all relevant options — may find additional guidance in our article on multiple myeloma treatment after relapse, which covers the decision process at that stage in more detail.

Frequently Asked Questions